Mass Spectrometry

Latest News

Kelsey Williams is a postdoctoral researcher at Los Alamos National Laboratory (LANL). Photo Credit: © Kelsey Williams.
The Future of Laser-Based Technologies in Space Exploration: An Interview with Kelsey Williams, Part IV

May 2nd 2025

In this extended Q&A interview, we sit down with Kelsey Williams, a postdoctoral researcher at Los Alamos National Laboratory (LANL), who is working on planetary instrumentation using spectroscopic techniques such as laser-induced breakdown spectroscopy (LIBS) and laser ablation molecular isotopic spectrometry (LAMIS). In the final part of our conversation with Williams, she discusses how laser-based spectroscopic techniques might be used in the future to advance space exploration.

Kelsey Williams is a postdoctoral researcher at Los Alamos National Laboratory (LANL). Photo Credit: © Kelsey Williams.
The Role of LIBS in ChemCam and SuperCam: An Interview with Kelsey Williams, Part III

May 2nd 2025

Kelsey Williams is a postdoctoral researcher at Los Alamos National Laboratory (LANL). Photo Credit: © Kelsey Williams.
The Potential of Mass Spectrometry in Planetary Exploration: An Interview with Kelsey Williams, Part II

May 2nd 2025

Kelsey Williams is a postdoctoral researcher at Los Alamos National Laboratory (LANL). Photo Credit: © Kelsey Williams.
The Role of LIBS and Mass Spectrometry in Planetary Exploration: An Interview with Kelsey Williams, Part I

May 2nd 2025

Graphical representation of air quality index and monitoring © stokkete-chronicles-stock.adobe.com
High-Speed Laser MS for Precise, Prep-Free Environmental Particle Tracking

April 21st 2025

More News


table2-web.jpg

The Role of Liquid Chromatography–Mass Spectrometry in the Characterization of Therapeutic Monoclonal Antibodies

May 1st 2016

Monoclonal antibodies (mAbs) have been increasingly used as biotherapeutic agents and a number of new mAbs are currently in the drug pipeline. Over the next five years the patent on at least nine major biotherapeutic monoclonal antibodies will expire, opening the door for development and marketing of generic forms known as Biosimilars. In this paper a review of the central role mass spectrometry coupled to liquid chromatography plays in characterizing these antibodies is presented. Contemporary top down and middle-up approaches using mass spectrometry and various novel separation techniques to measure the intact masses of mAbs and their subunits or domains are highlighted. Example data of an innovator mAb, Humira (adalimumab) are presented showing the identities and relative abundances of the isoforms associated with this mAb. Similarly the current state of classical peptide mapping using reversed-phase chromatography and tandem mass spectrometry with scan- dependent acquisition is briefly reviewed. Novel approaches that speed analysis and provide information on post translational modifications, glycosylation, and disulfide mapping are discussed. Example data of stressed and unstressed samples of adalimumab are also presented to demonstrate peptide mapping data and modifications to the antibody. Lastly, the current use of mass spectrometry in glycoprofiling of mAbs is reviewed. Example glycan data for adalimumab generated by a novel labeling scheme and sensitive to detection by both fluorescence and mass spectrometry will be presented.